Robert Kennedy Jr. signs recommendation eliminating mercury-based thimerosal from influenza vaccines, fulfilling anti-vaccine ...

Australian shares are set to open lower this morning after US stocks ended roughly flat overnight, as local traders await ...

Australian shares slipped off their all-time peak on Tuesday, dragged down by biotech major CSL’s steepest fall ...

Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and ...

Australia’s largest pharmaceutical company plans to spin off its Seqirus business into a separate ASX listing in the 2026 ...

CSL also said it would restart a multi-year share buyback program from FY26, beginning with A$750 million. Chief Executive ...

SYDNEY] Australian biotech giant CSL said that it will spin off its Seqirus vaccine business into a separately listed company ...

Australian biotech giant CSL Ltd. said it will spin off its Seqirus vaccine business into a separately listed company, as it reported full-year profit that was slightly higher than expected. CSL ...

Australian biotech giant CSL Ltd on Tuesday announced plans to demerge its influenza vaccine division, CSL Seqirus, and said it will lay off up to 15% of its workforce, after reporting a strong growth ...

New research projects funded to combat avian influenza in swine focus on vaccine development, transmission risks, and biosecurity measures.

The vaccine requires a prescription, which people can obtain by filling out a medical screening questionnaire through the ...

Australian biotech giant CSL said on Tuesday it plans to demerge its influenza vaccine division, CSL Seqirus, into a separately listed company by the end of the financial year 2026, alongside job cuts ...